MR‐Guidance of Gene Therapy for Brain Diseases: Moving From Palliative Treatment to Cures
Open Access
- 21 April 2025
- journal article
- review article
- Published by Wiley in Journal of Magnetic Resonance Imaging
- Vol. 62 (5) , 1280-1295
Abstract
Regulatory bodies in the U.S. and Europe recently approved a gene therapy for aromatic L‐amino acid decarboxylase (AADC) deficiency, a rare neurologic disorder where a genetic mutation prevents dopamine production in the brain. Affected children fail to develop normal motor and cognitive functions. MRI‐guided intraparenchymal delivery of AADC gene therapy to localized gray matter regions—specifically the substantia nigra and ventral tegmental area—has enabled the brain to produce dopamine, resulting in dramatic improvements in physical and cognitive outcomes. The need to target only a small brain region simplifies the surgical approach. However, gene therapy for broader neurodegenerative conditions has progressed more slowly than expected, despite significant global investment. Clinical efficacy depends heavily on the accurate delivery of gene therapeutics via direct brain infusion, cerebrospinal fluid (CSF) administration, or both. Inadequate image guidance during clinical trials makes it difficult to distinguish between true drug inefficacy and delivery failure. We highlight how increasing use of MRI for pre‐surgical simulation and real‐time therapy monitoring is accelerating gene therapy development for neurological diseases. This manuscript explores MRI's role in guiding intraparenchymal gene delivery, particularly using Convection Enhanced Delivery (CED). MRI contributes across the treatment timeline—from pre‐surgical planning and infusion guidance to validating therapeutic coverage. We describe how MRI supports controlled therapeutic distribution for localized treatments and its potential to enable broader distributions needed for correcting widespread genetic anomalies. We also detail how structural and anatomical MRI sequences (T1, T2, Time of Flight, and Diffusion Tensor Imaging (DTI)) can help model likely infusion distributions. Finally, we provide an outlook on how advanced DTI‐based algorithms and poroelastic theory could further improve modeling of infusion dynamics. Current MRI‐based technologies can be integrated and enhanced to improve CED effectiveness, especially in very young pediatric patients.Evidence Level: 1.Technical Efficacy: Stage 4.Keywords
This publication has 78 references indexed in Scilit:
- Real-Time Magnetic Resonance Imaging During Convective Gene Therapy Perfusion of the BrainJAMA Surgery, 2024
- Efficient numerical solutions of Neumann problems in inhomogeneous media from their probabilistic representations and applicationsEngineering Reports, 2020
- MR Biomarkers of Degenerative Brain Disorders Derived From Diffusion ImagingJournal of Magnetic Resonance Imaging, 2019
- Neurite orientation dispersion and density imaging (NODDI) and free‐water imaging in ParkinsonismHuman Brain Mapping, 2019
- Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE‐MRI derived biomarkers in multicenter oncology trialsJournal of Magnetic Resonance Imaging, 2018
- Evaluation of pressure‐driven brain infusions in nonhuman primates by intra‐operative 7 tesla MRIJournal of Magnetic Resonance Imaging, 2012
- Minimally invasive precision brain access using prospective stereotaxy and a trajectory guideJournal of Magnetic Resonance Imaging, 2008
- Intraoperative MR‐guided neurosurgeryJournal of Magnetic Resonance Imaging, 2008
- Prospective stereotaxy: A novel method of trajectory alignment using real‐time image guidanceJournal of Magnetic Resonance Imaging, 2001
- Interventional MRI at high‐field (1.5 T): Needle artifactsJournal of Magnetic Resonance Imaging, 1998